您好,欢迎访问中山大学肿瘤防治中心官方网站!
内部网 职工邮箱 图书馆 OA系统 医生门户 English
院士风采 首席专家 临床专家 科研学者 客座教授 人才名录
首页
  • 谢小明

    职务:乳腺科主任
    职称:教授,博士生导师
    专长:从事肿瘤和乳腺癌医疗、教学和科研工作二十多年,在乳腺疾病的诊断和治疗方面拥有丰富的经验。在肿瘤分子生物学和靶向治疗分子机制方面研究成绩突出。
        中山大学肿瘤防治中心乳腺科主任,中山大学“百人计划”引进人才,教授、博士研究生导师,华南肿瘤学国家重点实验室研究员,肿瘤生物技术研究室主任。美国M. D. Anderson癌症中心访问教授。2008年7月回国,与杨名添教授一起建立肿瘤防治中心乳腺科并担任主任。2009年9月建立华南肿瘤学国家重点实验室肿瘤生物技术研究室并担任主任,2009年与法国让佩林癌症中心建立中法癌症遗传学联合实验室并担任主任。目前是美国癌症研究协会(AACR)、美国临床癌症研究协会(ASCO)和美国基因治疗协会(ASGT)等会员,是《Chinese Journal of Cancer》编辑部责任编委、美国《Journal of Cancer》和《中华乳腺病杂志》责任编委,《Cancer Research》、《Human Gene Therapy》和《Annals of Surgical Oncology》等多家杂志的审稿人。是国家自然科学基金委一审、二审专家和广东省自然科学基金委评审专家,广东省医学鉴定专家,广州市医疗事故技术鉴定专家。

    医疗专长:
      从事肿瘤和乳腺癌医疗、教学和科研工作二十多年,在乳腺疾病的诊断、手术和综合治疗方面拥有丰富的经验。在肿瘤分子生物学和靶向治疗分子机制方面研究成绩突出。

    门诊时间:每周一、三上午。

      中山大学肿瘤防治中心乳腺科主任,中山大学“百人计划”引进人才,教授、博士研究生导师,华南肿瘤学国家重点实验室研究员,肿瘤生物技术研究室主任。美国M. D. Anderson癌症中心访问教授。2008年7月回国,与杨名添教授一起建立肿瘤防治中心乳腺科并担任主任。2009年9月建立华南肿瘤学国家重点实验室肿瘤生物技术研究室并担任主任,2009年与法国让佩林癌症中心建立中法癌症遗传学联合实验室并担任主任。目前是美国癌症研究协会(AACR)、美国临床癌症研究协会(ASCO)和美国基因治疗协会(ASGT)等会员,是《Chinese Journal of Cancer》编辑部责任编委、美国《Journal of Cancer》和《中华乳腺病杂志》责任编委,《Cancer Research》、《Human Gene Therapy》和《Annals of Surgical Oncology》等多家杂志的审稿人。是国家自然科学基金委一审、二审专家和广东省自然科学基金委评审专家,广东省医学鉴定专家,广州市医疗事故技术鉴定专家。

    联系电话:020-87343805; (Fax):020-87343805,Email:xxie1234@yahoo.com, xiexm@sysucc.org.cn.
    通讯地址:广州市东风东路651号 中山大学肿瘤防治中心乳腺科 邮编 510060。

    医疗专长:
      从事肿瘤和乳腺癌医疗、教学和科研工作二十多年,在乳腺疾病的诊断、手术和综合治疗方面拥有丰富的经验。在肿瘤分子生物学和靶向治疗分子机制方面研究成绩突出。门诊时间:每周一、三上午。

    个人简介:
      在中南大学湘雅医学院于1986年获医学学士学位,1994年获博士学位。1995-1997年在西班牙做博士后,1997-1999年在美国佛罗里达大学做博士后,1999-2003年在美国贝勒医学院任副研究员。2003-2008年在美国德州大学M. D. Anderson癌症中心任研究员,曾任分子和细胞肿瘤系转化研究课题组负责人,2010.9-2010.10在法国让佩林癌症中心合作研究。长期致力于癌症的基因调控,活体成像转基因动物模型和癌症的靶向基因治疗等方面研究,发展了多套新颖的对乳腺癌、胰腺癌、前列腺癌、卵巢癌、肝癌等多种癌症的靶向治疗策略和临床前期产品,与中国、美国、英国、日本、韩国及台湾地区的多家研究机构开展了广泛的交流和合作。
      共发表论著70余篇,其中SCI论著50余篇(包括Cancer Cell, Nature Cell Biology,Science Signaling, Caner Research,Oncogene, Human Gene Therapy,Mol Cancer Therapeutics, Cancer Gene Therapy,Molecular Endocrinology,Digestive Diseases and Science等)。中英文专业书籍3本中各一章。其中以通讯作者/第一作者发表论文总影响因子90余分,1篇大于20(Cancer Cell,2007),以第一作者和共同作者发表论文总影响因子累计超过300余分,他引共1000余次,其中第一作者论文单篇他引最高70余次,共同作者单篇他引最高80余次。其中纳米颗粒介导的VISA系统靶向治疗胰腺癌的主要研究成果,发表在2007年7月份的Cancer Cell(IF值24.9)上。美国Science News上评论:“这种治疗癌症的方法是独一无二的,对癌症既有非常强的疗效又非常特异”。美国ABC电视台认为“这是癌症治疗的一个重大突破”。在论文发表后短期内,来自美国<<世界日报>>,以及中 国、英 国、俄 国、德 国、法国、西班牙、葡萄牙、意大利、荷兰、希腊、阿拉伯、韩国、日本等世界各地的多家科学杂志和新闻媒体对该成就进行了200多次报道和高度的评价。已获得或申请中国美国发明专利11项,研制临床前期产品10项,其中1项已部分转让给美国Pfizer(辉瑞)制药公司,其中1项已经FDA批准,获许进入I期临床验证,已部分转让给台湾东洋制药公司,其中1项已部分转让广州制药公司共同开发。先后承担美国NIH、NCI重大课题5项。回国后,实施临床研究多项,主持中山大学II类引进人才基金、广州市科技计划、广东省自然基金、教育部博士点基金和国家自然基金面上和重点项目等30余项,经费600余万元。

    研究方向:
      1. 乳腺肿瘤的诊断及治疗,乳腺癌干细胞及纳米靶向治疗,乳腺肿瘤分子遗传学
      2. 肿瘤学和分子医学(肿瘤的发生发展机制,肿瘤早期诊断与生物治疗等)
      3. 细胞生物学
      4. 影像医学与生物医学工程
      5. 新型实验动物模型

    发明专利:
      1. 谢小明等。One type of the innovative syringe.中国专利号(1994): ZL 93233668.X.
      2. 谢小明等。CANCER SPECIFIC PROMOTERS (Including breast cancer and ovarian cancer). USPT Patent. 癌症靶向基因治疗乳腺癌和卵巢癌. 美国专利申请号(11.2007):119430572  (AO-UTSC:995US)
      3. 谢小明等。CANCER SPECIFIC PROMOTERS (Including breast cancer, pancreatic cancer, prostate cancer). USPT Patent. 癌症靶向基因治疗乳腺癌, 胰腺癌和卵巢癌. 美国专利号(2010):US7723104B2
      4. 谢小明等。EZC-prostate (a transgenic mouse model)(Disclosure). License to Pfizer (美国) 2005 
      5. 谢小明等。一种可高效高特异灭杀乳腺癌细胞的药物。中国专利号:201110371596.2。License to Guangzhou Pharmaceutical。
      6. 谢小明等。一种可高效在体内外转染基因的新型脂质体及其制备方法。中国专利申请号:201110300920.1
      7. 谢小明等。一种在肿瘤细胞中高效高特异表达靶基因的载体T-VISA。中国专利申请号:201110300441.X
      8. 谢小明等。一种可高效高特异灭杀乳腺癌细胞的药物T-VISA-PEA15。中国专利申请号:201210063812.1
      9. 谢小明等。一种可高效高特异灭杀P53基因突变型乳腺癌细胞的T-VISA-miR34脂质体。中国专利申请号:201210064390.X.

    承担研究基金:
      1. Co-Investigator, E1A Gene Therapy in Breast Cancer, RO1 CA058880, National Cancer Institute, NIH $261,000 ADC, 08/01/1997-01/31/2005.
      2. Co-Investigator, “Targeting Breast Cancer-Specific Gene Therapy’ in NIH SPORE grant in Breast Cancer (5P50CA116199-03), 2005-2010.
      3. Co-Investigator, “Development of Novel Gene Therapy for Pancreatic Cancer” in NIH SPORE grant in Pancreatic Cancer (P20 CA101936), P20 CA101936-01, NCI,NIH. $225,000 (ADC). 07/01/2003-06/30/2008.
      4. Co-Investigator. “Development of E1A Gene Therapy in Ovarian Cancer” in NIH SPORE grant in Ovarian Cancer (5P50CA083639-08), 2005-2010.
      5. Co-PI. Ideal Development Award ($560,000), DOD (Department of Defense).USA. 2007.
      6. Co-Investigator, Topfer Funds.2005-2010.
      7. Co-Investigator, M. D. Anderson Cancer Center Support Grant CA16672, 2005.
      8. Co-Investigator, NIH Grant R01-CA87569, Baylor College of Medicine, 2001-2006.
      9. PI谢小明. 中山大学“985” 计划(2008089)。乳腺癌纳米靶向治疗机制。80万元,2008-2010
      10. PI谢小明. 广东省自然基金。应用“VISA”系统高效靶向杀灭乳腺癌干细胞的研究(9151008901000124)。 5万元,2009-2011.
      11.PI谢小明. 教育部高等学校博士学科点专项科研基金.乳腺癌干细胞的生物学特征及靶向治疗研究(20090171110078)。6万元(2009).
      12. PI谢小明. 教育部回国人员启动基金. 乳腺癌靶向治疗。4万元 ,2009
      13. PI谢小明: 中国乳腺癌临床流行病学多中心研究。中国癌症基金会。5.5万元,2009.9-2010.12
      14. PI谢小明. EZC-乳腺癌干细胞转基因小鼠模型的建立及应用。国家自然基金重点项目(31030061)。200万,2011-2014.
      15. PI谢小明. 血清her-2/neu 水平在乳腺癌中的价值研究. 5万元, 2010.9-2011.8
      16. PI谢小明. CD44-VISA-miR-200c高效纳米系统靶向杀灭乳腺癌干细胞的研究.。广州市科技计划。6万元,2010-7-2012.6
      17. 肖祥胜,谢小明等.“VISA-miRNA”系统靶向杀灭乳腺癌干细胞的研究.。省卫生厅项目。1 万元,2010-2011
      18. PI.谢小明. 含有1,8-萘酰亚胺单体的聚乙烯亚胺类非病毒基因载体的研究。华南肿瘤学重点实验室。5万元,2009-2010
      19. PI 谢小明。前列腺癌细胞系肿瘤干细胞的分离、鉴定及其生物学特性和相关机制研究。5万元,2010-2011
      20. PI谢小明。乳腺癌靶向治疗的研究。华南肿瘤学重点实验室.。15万元,2010-2011
      21. PI谢小明. 乳腺癌靶向治疗的研究。华南肿瘤学重点实验室。 8万元,2011-2012
      21. PI谢小明. 乳腺癌靶向治疗的研究,华南肿瘤学重点实验室。8万元,2012-2013
      22. PI谢小明. VISA-miR-34a高效纳米系统靶向杀灭乳腺癌干细胞的作用及机制研究。国家自然基金面上项目(81272514)。65万,2013-2016.

    临床试验:  
     2003-Present  乳腺癌临床试验
       1. E1A gene therapy for breast cancer; E1A 基因治疗乳腺癌
       2. BikDD gene therapy for breast cancer. BikDD基因治疗乳腺癌 (prepared, under process of FDA)
      3. E10A (Adenovirus expressing human endostatin) for recurrent breast cancer therapy (approved by SFDA)..
      4. 喜滴克治疗乳腺癌的IV期临床试验, 2011-2012
     
     2005-present  胰腺癌临床试验
       1. BikDD gene therapy for pancreatic cancer. BikDD基因治疗胰腺癌 (prepared, under process of  FDA)

     2005-present  卵巢癌临床试
       1. E1A gene therapy and SAHA for ovarian cancer. E1A 基因治疗和SAHA治疗卵巢癌
       2. BikDD gene therapy for ovarian cancer. BikDD基因治疗卵巢癌 (prepared, under process of  FDA)

    代表性论文(第一和/或通讯作者(?)):
      1. Gao J, Li L, Wu M, Liu M, Xie X, Guo J, Tang H, Xie X(?). MiR-26a Inhibits Proliferation and Migration of Breast Cancer through Repression of MCL-1. PLoS One. 2013 Jun 4;8(6):e65138. doi: 10.1371/journal.pone.0065138. Print 2013. (IF:4.01)
      2. Guo J, Li W, Shi H, Xie X, Li L, Tang H, Wu M, Kong Y, Yang L, Gao J, Liu P, Wei W, Xie X(?). Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a. Mol Cell Biochem. 2013 Jun 15. [Epub ahead of print].
      3. Kong Y, Wang J, Liu W, Chen Q, Yang J, Wei W, Wu M, Yang L, Xie X, Lv N, Guo J, Li L, Gao J, Xie X(?), Dai S(?). Cytokeratin19-2g2, a novel fragment of cytokeratin19 in serum, indicating a more invasive behavior and worse prognosis in breast cancer patients. PLoS One. 2013;8(2):e57092. doi: 10.1371/journal.pone.0057092. (IF:4.01)
      4. Li L, Yuan L, Luo J, Gao J, Guo J, Xie X(?). MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med. 2013 May;13(2):109-17..(IF:2.000)
      5. Wu MQ, Hu P, Gao J, Wei WD, Xiao XS, Tang HL, Li X, Ge QD, Jia WH, Liu RB, Xie XM(?).Low expression of tyrosine-protein   phosphatase nonreceptor type 12 is associated with lymph node metastasis and poor prognosis in operable triple-negative breast cancer. Asian Pac J Cancer Prev. 2013;14(1):287-92.
      6. Li L, Xie X, Luo J, Wei W , Xi S, Guo J, Kong Y, Wu M, Gao J, Xie Z, Tang J, Wang X, Yang M, Hung MC, X Xie (?). Targeted Expression of miR-34a by T-VISA System Suppresses Tumor Cell Growth and Invasion in Breast Cancer. Mol Therapy; 2012; 20(12):2326-2334 (IF:6.873)
      7. Xie X, L Li, X Xiao, J Guo, Y Kong, M Wu, W Liu, G Gao, J L. Hsu, W Wei, M-C Hung (?) and X Xie(?). Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Mol Cancer Ther.2012 ;11(9);1915-1924. (IF:5.226)
      8. Wu M, Wei W, Xiao X, Guo J, Xie X, Li L, Kong Y, Lv N, Jia W, Zhang Y, Xie X(?). Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol. 2012 ; 3240-3249 (IF:2.14)
      9. Su Y, Tang LY, Chen LJ, He JR, Su FX, Lin Y, Chen WQ, Xie X(?), Ren ZF(?). Joint Effects of Febrile Acute Infection and an Interferon-γ Polymorphism on Breast Cancer Risk. PLoS One. 2012;7(5):e37275. (IF:4.092)
      10. Kong Y, Dai S, Xie X, Xiao X, Lv N, Guo J, Li L, Jia W, Zhang Y, Liu W, Wei W, Xie X(?). High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. J Cancer Res Clin Oncol. 2012; 2012;138(2):275-84. (IF:2.558)
      11. Lv N, Lin S, Xie Z, Tang J, Ge Q, Wu M, Xie X, Xie X(?)., Wei W(?). Absence of evidence for epidermal growth factor receptor and human homolog of the Kirsten rat sarcoma-2 virus oncogene mutations in breast cancer. Cancer Epidemiol. 2012;36(4);341-346. (IF:2.010)
      12. Xie X, Guo J, Kong Y, Xie GX, Li L, Lv N, Xiao X, Tang J, Wang X, Liu P, Yang M, Xie Z, Wei W, Xie X(?).Targeted expression of E. coli purine nucleoside phosphorylase and Fludara for prostate cancer therapy. J Gene Med. 2011;13:680-691. (IF:3.079)
      13. Xie X(?), J.L Hsu, M-G Choi, W Xia, H Yamaguchi, C-T Chen, Z Lu, N T. Ueno, JK. Wolf, RC. Bast, Jr. and M-Ch Hung. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Therapeutics. 2009; 8(8):2375-82. (IF: 5.225).
      14. Xie, X(?)., Xia, W., Li, Z., Kuo, H-P.,Liu, Y., Li, Z., Ding, Q., Zhang, S., Spohn, W., Yang, Y., Wei, Y., Lang, J-Y., Evans, D.B., Chiao, P.J., Abbruzzese J.L. and Hung, M-C. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell, 2007;12(July10):52-65. (IF: 26.925).
      15. Xie, X(?), Z Luo, KM Slawin, and DM Spencer. The EZC-Prostate Model: Non-invasive prostate imaging in living mice. Mol   Endocrinol 2004;18(3):722-732. (IF:5.389).
      16. Xie X(?), X Zhou, Y Liu, K Slawin, and D Spencer. Adenovirus-mediated tissue-targeted expression of a caspase 9-based artificial death switch for the treatment of prostate cancer. Cancer Res 2001; 61: 6795-804. (IF: 8.234).
      17. Xie X(?), X Zhao, Y Liu, CYF Young, DJ Tindall, K Slawin, and D Spencer. Robust prostate-specific expression for targeted gene therapy based on human kallikrein 2 (hK2) promoter. Human Gene Therapy 2001;12(5): 549-61. (IF: 4.829).
      18. Xie X(?), CE Forsmark, and JY Lau. Effect of bile and pancreatic juice on adenovirus-mediated gene delivery: Implications on the feasibility of gene delivery through ERCP. Digestive Diseases and Sciences 2000; 45(2):230-36. (IF:1.583).
      19. Zhang B, Song Q, Zhang B, Tang Z, Xie X, Yang H, He J, Li H, Li J, Li J, Fan J, Huang R, Zhang H, Qiao Y. A 10-year (1999 ~ 2008) retrospective multi-center study of breast cancer surgical management in various geographic areas of China. Breast. 2013 Feb 4. doi:pii: S0960-9776(13)00006-4. 10.1016/j.breast.2013.01.004. [Epub ahead of print].
      20. Cen YL, Qi ML, Li HG, Su Y, Chen LJ, Lin Y, Chen WQ, Xie XM, Tang LY, Ren ZF. Associations of polymorphisms in the genes of FGFR2, FGF1, and RBFOX2 with breast cancer risk by estrogen/progesterone receptor status. Mol Carcinog. 2012 Nov 9. doi: 10.1002/mc.21979. [Epub ahead of print]
      21. Wang SL, Li YX, Zhang BN, Li J, Fan JH, He JJ, Song QK, Zhang P, Zheng S, Zhang B, Yang HJ, Xie XM, Tang ZH, Li H, Li JY, Qiao YL. Epidemiologic study of radiotherapy use in China in patients with breast cancer between 1999 and 2008. Clin Breast Cancer. 2013 Feb;13(1):47-52. doi: 10.1016/j.clbc.2012.09.012. Epub 2012 Oct 25.
      22. Ge QD, Lv N, Kong YN, Xie XH, He N, Xie XM, Wei WD. Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases. Asian Pac J Cancer Prev. 2012;13(10):5081-6.
      23. Ma X, Beeghly-Fadiel A, Lu W, Shi J, Xiang YB, Cai Q, Shen H, Shen CY, Ren Z, Matsuo K, Khoo US, Iwasaki M, Long J, Zhang B, Ji BT, Zheng Y, Wang W, Hu Z, Liu Y, Wu PE, Shieh YL, Wang S, Xie X, Ito H, Kasuga Y, Chan KY, Iwata H, Tsugane S, Gao YT, Shu XO, Moses HL, Zheng W. Pathway Analyses Identify TGFBR2 as Potential Breast Cancer Susceptibility Gene: Results from a Consortium Study among Asians. Cancer Epidemiol Biomarkers Prev. 2012 May 21. [Epub ahead of print] (IF:4.123)
      24. Wang Q, Li J, Zheng S, Li JY, Pang Y, Huang R, Zhang BN, Zhang B, Yang HJ, Xie X, Tang ZH, Li H, He JJ, Fan JH, Qiao YL. Breast cancer stage at diagnosis and area-based socioeconomic status: a multicenter 10-year retrospective clinical epidemiological study in China. BMC Cancer. 2012 Mar 29;12:122. (IF:3.153)
      25. Long J, Cai Q, Sung H, Shi J, Zhang B, Choi JY, Wen W, Delahanty RJ, Lu W, Gao YT, Shen H, Park SK, Chen K, Shen CY, Ren Z, Haiman CA, Matsuo K, Kim MK, Khoo US, Iwasaki M, Zheng Y, Xiang YB, Gu K, Rothman N, Wang W, Hu Z, Liu Y, Yoo KY, Noh DY, Han BG, Lee MH, Zheng H, Zhang L, Wu PE, Shieh YL, Chan SY, Wang S, Xie X, Kim SW, Henderson BE, Le Marchand L, Ito H, Kasuga Y, Ahn SH, Kang HS, Chan KY, Iwata H, Tsugane S, Li C, Shu XO, Kang DH, Zheng W. Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer. PLoS Genet. 2012 Feb;8(2):e1002532. Epub 2012 Feb 23. (IF :9.543 )
      26. Shao YZ, Liu LZ, Bie MJ, Li CC, Wu YP, Xie X, Li L. Characterizing the clustered microcalcifications on mammograms to predict the pathological classification and grading: a mathematical modeling approach. J Digit Imaging. 2011 Oct;24(5):764-71. (IF:1.413 )
      27. Lv N, Xie X, Ge Q, Lin S, Wang X, Kong Y, Shi H, Xie X, Wei W. Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations. Diagn Pathol. 2011 Dec 2;6(1):118. (IF: 1.388)
      28. Liu Y, Lang F, Xie X, Prabhu S, Xu J, Sampath D, Aldape K, Fuller G, Puduvalli VK. Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts. Cell Death Dis. 2011 Feb 24;2:e121.(IF:5.333)
      29. Li J, Zhang BN, Fan JH, Pang Y, Zhang P, Wang SL, Zheng S, Zhang B, Yang HJ, Xie X, Tang ZH, Li H, Li JY, He JJ, Qiao YL. A Nation-Wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in china. BMC Cancer. 2011 Aug 22;11:364. (IF:3.153)
      30. Xie ZM, Li LS, Laquet C, Penault-Llorca F, Uhrhammer N, Xie X, Bignon YJ. Germline mutations of the E-cadherin gene in families with inherited invasive lobular breast carcinoma but no diffuse gastric cancer. Cancer. 2011; 117 (14): 3112-17.(IF: 5.131)
      31. Xiao X, Shi D, Liu L, Wang J, Xie X, Kang T, Deng W. Quercetin suppresses cyclooxygenase-2 expression and angiogenesis through inactivation of P300 signaling. PLoS One. 2011;6(8):e22934. Epub 2011 Aug 8. (IF: 4.411)
      32. Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, Yamaguchi H, Xie X, Woodward WA, Yu D, Hortobagyi GN, Hung MC. BikDD Eliminates Breast Cancer Initiating Cells and Synergizes with Lapatinib for Breast Cancer Treatment. Cancer Cell. 2011 Sep 13;20(3):341-56.( IF: 26.925)
      33. Cai Q, Long J, Lu W, Qu S, Wen W, Kang D, Lee JY, Chen K, Shen H, Shen CY, Sung H, Matsuo K, Haiman CA, Khoo US, Ren Z, Iwasaki M, Gu K, Xiang YB, Choi JY, Park SK, Zhang L, Hu Z, Wu PE, Noh DY, Tajima K, Henderson BE, Chan KY, Su F, Kasuga Y, Wang W, Cheng JR, Yoo KY, Lee JY, Zheng H, Liu Y, Shieh YL, Kim SW, Lee JW, Iwata H, Le Marchand L, Chan SY, Xie X, Tsugane S, Lee MH, Wang S, Li G, Levy S, Huang B, Shi J, Delahanty R, Zheng Y, Li C, Gao YT, Shu XO, Zheng W.Genome-wideassociation study identifies breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium. Hum Mol Genet. 2011 Dec 15;20(24):4991-9. (IF : 8.058)
      34. Ding Q, Chang CJ, Xie X, Xia W, Yang JY, Wang SC, Wang Y, Xia J, Chen L, Cai C, Li H, Yen CJ, Kuo HP, Lee DF, Lang J, Huo L, Cheng X, Chen YJ, Li CW, Jeng LB, Hsu JL, Li LY, Tan A, Curley SA, Ellis LM, Dubois RN, Hung M.APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest. 2011 Nov 1;121(11):4526-36. (IF : 14.152)
      35. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN, Hung MC. EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β Catenin Signaling. Cancer Cell. 2011;19:86-100 ( IF: 26.925)
      36. Song H, Li CW, Labaff AM, Lim SO, Li LY, Kan SF, Chen Y, Zhang K, Lang J, Xie X, Wang Y, Huo LF, Hsu SC, Chen X, Zhao Y, Hung  MC. Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors. Biochem Biophys Res Commun. 2011 Jan 7;404(1):68-73. (IF:2.595)
      37. Tang J, X Xie, X Wang,  Z Xie, J He, Y Wu, W Fan, J Fu and M Yang. Radiocolloid in combination with methylene dye localization, rather than wire localization, is a preferred procedure for excisional biopsy of nonpalpable breast lesions. Ann Surg Oncol. 2011 Jan;18(1):109-13. (IF :4.182)
      38. Kuo HP, Lee DF, Chen CT, Liu M, Chou CK, Lee HJ, Du Y, Xie X, Wei Y, Xia W, Weihua Z, Yang JY, Yen CJ, Huang TH, Tan M, Xing G, Zhao Y, Lin CH, Tsai SF, Fidler IJ, Hung MC. ARD1 Stabilization of TSC2 Suppresses Tumorigenesis Through the mTOR Signaling Pathway. Science Signaling. 2010 Feb 9;3(108). ( IF: 6.354)
      39. Sher YP, T-F Tzeng, S-F Kan, J Hsu, X Xie, Z Han, W-C Lin, L-Y Li, and M-C Hung. Cancer Targeted Gene Therapy of BikDD Inhibits Orthotopic Lung Cancer Growth and Improves Long-Term Survival. Oncogene. 2009;28(37):3286-95. (IF :7.216).
      40. Yang, J-Y., Zong, C.S., Xia, W., Yamaguchi, H., Ding, Q., Xie, X., Lang, J-Y., Lai, C-C., Chang, C-J., Huang, W-C., Huang, H., Kuo, H-P., Lee, D-F., Li, L-Y., Lien H-C., Cheng, X, Chang, K-J., Hsiao, C-D., Tsai, F-J., Tsai, C-H., Sahin, AA., Hortobagyi, GN., Yu, D., Muller, WJ., Mills, GB., and Hung, M-C. Erk promotes tumorigenesis by inhibiting Foxo3a via MDM2-mediated degradation. Nature Cell Biology. 2008; 10(2):138-48.. (IF:19.47).
      41. Ding, Q., He, X., Xia, W., Hsu, J-M., Chen, C-T., Li, L-Y., Lee, D-F., Yang, J-Y., Xie, X., Liu, J-C., and Hung, M-C. Mcl-1 inversely correlates with GSK-3β activity and associates with poor prognosis in human breast cancer. Cancer Research, 2007;67(10):4564-71. (IF:8.234).
      42. Seethammagari, M. R., Xie, X., Greenberg, N. M., and Spencer, D. M. (2006). EZC-prostate models offer high sensitivity and specificity for noninvasive imaging of prostate cancer progression and androgen receptor action. Cancer Res 2006;66, 6199-6209. (IF: 8.234).
      43. Ou-Yang, F., Lan, K. L., Chen, C. T., Liu, J. C., Weng, C. L., Chou, C. K., Xie, X., Hung, J. Y., Wei, Y., Hortobagyi, G. N., Hung, M-C. Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells. Cancer Res 2006; 66, 378-384. (IF:8.234).
      44. Day, C. P., Rau, K. M., Qiu, L., Liu, C. W., Kuo, H. P., Xie, X., Lopez-Berestein, G., Hortobagyi, G. N., and Hung, M. C.. Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Ther 2006;13, 706-719. (IF: 3.744).
      45. Tuttle, D. L, CR Coberley, X Xie, ZC Kou, JW Sleasman, and MM Goodenow. Effects of human immunodeficiency virus type 1 infection on CCR5 and CXCR4 coreceptor expression on CD4 T lymphocyte subsets in infants and adolescents. AIDS Res Hum Retroviruses. 2004. 20(3): 305-13. (IF : 2.139).
      46. Zhao T, XM Rao, X Xie, L Li, T Thompson, KM McMasters, and HS Zhou. Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo. Cancer Res 2003;63(12):3073-8. (IF:8.234).
      47. M Drozdzik, C Qian, X Xie, JJ Lasarte, J Prieto. Gene therapy of hepatoma model by combination of adenovirus expressing the HSV thymidine kinase and interleukin-12. J Hepatology. 2000; 32(2): 379-86. (IF:9.334)
      48. Mazzolini G, C Qian, I Narvaiza, M Barajas, F Borras-Cuesta X Xie, M Duarte, I Melero and J Prieto. Adenoviral gene transfer of Interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effect level. Human Gene Therapy 2000; 11:113-25. (IF: 4.829).
      49. Lasarte JJ, FJ Corrales, N Casares, A Lopez-Diaz de Cerio, C Qian, X Xie, F Borras-Cuesta, and J Prieto. Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministrered antigen: the role of nitric oxide. J Immunology, 1999; 162:5270-5277. (IF:5.745)
      50. Mazzolini G, C Qian, X Xie, Y Sun, JJ Lasarte M, Drozdzik, J Prieto. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Therapy, 1999; 6(6): 514-22. . (IF: 3.744)
      51. Lau J Y-N, X Xie, MMC Lai, and PC Wu. Apoptosis and viral hepatitis. Seminar in Liver Disease 1998; 18(2):169-176.(IF : 7.053)
      52. 谢新华,韦尉东,孔亚楠,郭姣丽,吕宁,唐军,肖祥胜,谢小明*。药物代谢酶CYP2D6在他
    莫西芬个体化治疗中的研究进展。中华乳腺病杂志。 2011;5(5):49-55
      53. 尹军,唐军,王曦,谢泽明,连臻强,谢小明,杨名添。乳晕下注射示踪剂行前哨淋巴结活检的可行性。 中华乳腺病杂志,2008,2(5):514-519。
      54. 夏良平,周菲菲,杨名添,谢小明.乳腺癌中基因标签研究的共性问题.国际肿瘤学杂志, 2009.36(4)。
      55. 韦尉东 谢小明. 后曲妥珠单抗时代的乳腺癌靶向治疗.广东医学。2010;31(2). 133-136。
      56. 吕宁,孔亚楠,谢小明,韦尉东。乳腺癌抗-EGFR 治疗的机制和临床进展。广东医学。2010;31(21)2874-2876。
      57. 肖祥胜 李峻 王曦 韦尉东 唐军 刘鹏 谢小明。青年乳腺癌209例生存分析。中国医师进修杂志。 2010.
      58. 谢小明, 苏先狮, 张铮. 逆转录-套式-聚合酶链反应检测HCV RNA正链和负链及与肝细胞癌的关系. 中华传染病杂志. 1996; 14(4): 211-213
      59. 蔡太生,谢小明,王丽. 慢性乙肝病人的心理健康状况及相关因素的调查分析. 中国临床心理学杂志. 1996; 4(2): 111-113
      60. 谢小明,苏先狮, 张铮. 丙型肝炎病毒与肝细胞癌关系的分子生物学研究进展. 国外医学:生理病理科学与临床分册. 1995; 15(2): 106-108
      61. 谢小明, 苏先狮, 张铮, 郑宣鹤, 杨旭, 曾晓波, 陈一德, 李良友, 刘国清, 皮执民, 黄江生.肝癌患者丙型肝炎病毒感染的研究. 中国现代医学杂志. 1994; 4(1): 27-28
      62. 谢小明, 苏先狮,张铮, 郑宣鹤, 陈一德. 聚合酶链反应研究丙型肝炎病毒与肝癌的关系. 中华传染病杂志.1994; 12(3): 169-170
      63. 谢小明, 苏先狮, 陈一德, 李良友, 郑宣鹤, 曾滑, 吴卫民, 刘远芳. 肝癌患者血清乙型肝炎病毒标志物和抗丙型肝炎病毒抗体的检测及其相互关系. 医学临床研究. 1994; 11(2): 64-66
      64. 郑煜煌, 金一平, 谢小明, 张雪梅, 蒋芳清, 王计全 , 易长庚. 甲型肝炎患者外周血T淋巴细胞集落和T淋巴细胞亚群的观察. 中华传染病杂志. 1994; 12(1): 49-50
      65. 谢小明. 无症状供血者和慢性丙型肝炎患者血清HCV RNA的定量研究. 国际流行病学传染病学杂志. 1993; 20(5): 228-228
      66. 谢小明, 郑煜煌, 刘远芳, 金一平, 刘雪梅, 蒋芳清, 王计垒, 易长庚. 甲型肝炎患者外周血T淋巴细胞亚群的观察. 医学临床研究. 1993; 10(5): 260-261
      67. 谢小明, 苏先狮, 张铮, 陈一德, 李良友, 郑宣鹤, 刘国清, 皮执民, 周健平, 齐海智. 乙型、丙型和丁型肝炎病毒与肝细胞癌岛关系. 中西医结合肝病杂志. 1993;3 (2): 6-7
      68. 苏先狮, 谢小明, 陈一德, 杨观生. 湖南供血员和肝病患者1272例血清抗HCV检测及甲乙丙丁各型肝炎混合感染的研究. 临床肝胆病杂志. 1993; 9(1): 10-11
      69. 苏先狮, 郑宣鹤, 钱焕英, 王谷丰, 邓纯, 刘丽霞, 彭兰莎, 谢小明. 肝脏刺激生长素(HSS)治疗病毒性肝炎300例的临床研究. 临床肝胆病杂志. 1992; 8(3): 126-127
      70. 郑煜煌, 谢小明. 甲型肝炎患者外周血T淋巴细胞集落的观察. 广西医学, 1992; 6(6): 4-5
      71. 郑宣鹤, 龚国忠, 何艳, 黄道芩, 谢小明.急性肝炎重型并发急性容血性贫血和类白血病反因二例. 中华传染病杂志. 1991; 9(1): 32-33
      72. 郑煜煌, 谢小明, 张永红, 何艳. 病毒性肝炎患者中肥达反应的动态观察. 医学临床研究. 1990; 7(3): 167-169

    专著:
      1. 谢小明等。乳腺癌个体化治疗(第十八章)《肿瘤个体化医学原则》,人民卫生出版社。 2013;227-241
      2. 谢小明等。乳腺疾病相关的分子生物学(第三章第四节)《现代乳腺外科》, 人民卫生出版社2013
      3. Mien-Chie Hung, JL Hsu, CH Chao, Xiaoming Xie. Advances in Liposome-Based Targeted Gene Therapy of 《Cancer Recent Advances in Cancer Research and Therapy》,Elsevier,18 May 2012

    部分国际会议(*为第一作者或通信作者文摘):
      *1. The 8th International Conference on Viral Hepatitis. Xie X, X  Su, et al. A comparative study of on the relationship of HBV, HCV and HDV with hepatocellular carcinoma. Beijing, China. 1993北京
      *2. The annual meeting of the Association for the Study of Liver Diseases. Xie, et al. In vivo gene transfer to hepatocullular carcinoma in experimental animal models by adenoviral vector. London, 1996. 伦敦
      *3. The 2rd annual meeting of the Europe Society of Gene Therapy. X Xie, M Idoato and J Prieto. In vivo gene transfer to hepatocullular carcinoma by adenoviral vector. London, 1998. 西班牙
      *4. The 48th annual meeting of the American Association for the Study of Liver Diseases. Xie X, CE Forsmark and JYN Lau. Feasibility of adenoviral-mediated gene delivery through EGFP: the effect of bile and pancreatic juice. Chicago, USA, 1997. 芝加哥
      *5. The 6th Conference on retroviruses and Opportunistic Infections. Xie X, D Turtle, J.W. Sleasman and M.M. Goodenow . CD4 T lymphocytes that coexpress CD45RO and CD45RA are the primary target cells for infection by HIV-1. Chicago, USA, 1999. 芝加哥
      *6. The 3rd annual meeting of the American Society of Gene Therapy, Xie X, Spencer D. Robust prostate cell-specific expression based on human kallikrein 2(hK2) has been developed for targeted gene therapy. Denver, USA, 2000. 丹佛
      *7. The 4th annual meeting of the American Society of Gene Therapy, Xie X, Spencer D. Adenovirus-mediated tissue-targeted  expression of a caspase 9-based artificial death switch for the treatment of prostate cancer. Seattle, USA, 2001. 西雅图
      *8. The 5th annual meeting of the American Society of Gene Therapy, Xie X, Spencer D. Novel gene therapy for prostate cancer: in vivo-targeted expression of the E.Coli purine nucleoside phsophorylase gene by adenoviral delivery. Boston, USA, 2002. 波士顿
      *9. The 6th annual meeting of the American Society of Gene Therapy, Xie X, Spencer D. Novel prostate model. Washington DC, USA, 2003. 华盛顿
      *10. The 8th annual meeting of the American Society of Gene Therapy, Xie X, et al. Targeted prostate cancer gene therapy (oral presentation). St. Louis, USA, 2005圣路易斯
      *11. The 10th annual meeting of the American Society of Gene Therapy, Xie X, et al. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models (oral presentation). Seattle, USA, 2007. 西雅图
      *12. IMPcCT (Innovative Minds in Prostate Cancer Today), Department of Defense. Xie X, et al. Targeted expression of BikDD cures AIPC and ADPC in noninvasive imaging models. Atlanta, USA, 2007.
    13. The 5th Chinese Conference on Cancer and International Gene Therapy. Shijianzhuan, Hebei,China, 2008.
      *14. The 15th World Congress on Breast Diseases and 3rd Shanghai Breast Cancer Symposium. Shanghai, China, Oct. 2008. 上海
      *15. The San Antonio Breast Cancer Symposium at An Antonio, USA. Dec 10-15. 2008. 圣奥东尼奥
      *16.  The 5th Conference on Cancer Translational Research. Xie et al.  “VISA” nanopaticles to breast cancer.  Feb. 19-21. 2009. Macau.
      *17. The St Gallen Oncology Conference in Switzerland.  March 11-15, 2009. 瑞士
      *18. The 45th Annual Meeting of the American Society of Clinical Oncology. Orlando, USA. May 28-June 3.  2009. 奥尔兰多
      *19. the 14th Annual Scientific Symposium of Hong Kong Cancer Institute-Breast Cancer Symposium. Xie X, et al.“VISA” nanopaticles targeting to breast cancer. Nov. 11-14. Hong Kong. 香港
      *20. The San Antonio Breast Cancer Symposium at San Antonio. Xiaoming Xie,  et al. “VISA” nanopaticles to breast cancer. USA. Dec 9-14. 2009. 圣奥东尼奥
      *21. The 46th Annual Meeting of the American Society of Clinical Oncology. “VISA” nanopaticles to breast cancer  in animal models. Chicago, USA. June 3-June 8. 2010. 芝加哥
      *22. The San Antonio Breast Cancer Symposium at San Antonio. Xiaoming Xie,  et al. “VISA” nanopaticles targeting to breast cancer in vitro and in animal models. USA. Dec 8-12. 2010. 圣奥东尼奥
      *23. The 47th Annual Meeting of the American Society of Clinical Oncology. “VISA” nanopaticles to breast cancer in animal models. Chicago, USA. June 3-June 8. 2011. 芝加哥
      *24. The 16th Annual Scientific Symposium of Hong Kong Cancer Institute-Breast Cancer Symposium. Xie X, et al.“VISA-miRNAs” nanopaticles target to breast cancer. Nov. 4-6. Hong Kong. 香港
      *25. The San Antonio Breast Cancer Symposium at San Antonio. Xiaoming Xie,  et al.. USA. Dec 6-10. 2011. 圣奥东尼奥
      *26. The 48th Annual Meeting of the American Society of Clinical Oncology. “VISA” nanopaticles to breast cancer in animal models. Chicago, USA. June 1-5. 2012. 芝加哥
      *27. The 2nd  International Conference on Cell Science and Stem Research. “VISA-BikDD” and “VISA-miRNA” nanoparticles targeting to breast cancer and breast cancer stem cells. Invited Speaker. San Antonio. OMICS Group Conference. USA. Nov. 14-15, 2012. 圣奥东尼奥
      *28. The San Antonio Breast Cancer Symposium at San Antonio. VISA-miRNA and VISA-BikDD nanopaticles targeting to breast cancer.. USA. Dec 4-8. 2012. 圣奥东尼奥

    新闻与报道:
      1. 纳米颗粒介导的VISA系统靶向治疗胰腺癌的主要研究成果,已发表2007年7月份的Cancer Cell
    (IF:24.962)上。美国约翰霍普金斯大学医学院的胰腺癌专家Scott E. Ken教授,在 Science News 上评论:
    “这种治胰腺癌的方法是独一无二的,对胰腺癌既有非常强的疗效又非常特异”。
      2. 美国ABC电视台认为“是胰腺癌治疗的一个重大突破”。
      3. 来自美国、中国、俄 国、德 国、法国、西班牙、葡萄牙、意大利、荷兰、希腊、阿拉伯、韩国
    本等世界各的科学杂志和新闻媒体对该成就纷纷进行了200多次报道,并给予了高度的价。
      4. 中国医学论坛。2010.11
      5. 广东医师协会。 2010.9
      6. 南方都市报。2008.10
      7. 羊城晚报。 2012.3

    部分获奖:
      1. the 14th Hong kong Breast Cancer Conference 最佳奖, 2011, 香港.
      2. AstraZeneca Award ($50,000). USA. 2005. 美国.
      3. First prize, the 10th Annual Oncology Research Seminar. USA. 2001. 美国.
      4. Travel Grant, the 6th Conference on retroviruses and Opportunistic Infections, USA. 1999. 美国.
      5. The best oral presentation award. Terapia genica del hepatocarcinoma mediate la transferencia del gen  la interlukina 12 y timidin kinasa mediada por adenovirus.Madrid, Spain. 1998. 西班牙.
      6. Dr. Sir Q.W. Lee fellowship. USA. 1997. 美国.
      7. Dr. Li Zhengbie’s Fellowship. China. 1994. 长沙.
      8. Challenge Cup of China’s invention. China.1993. 挑战杯奖,上海.
      9. <<湘楚青年科技名人录>> (1993年).
      10. <<当代发明家成果辞典>> (1994年).
      11. <<当代科学家与发明家大词典>> (1994年).
      12. <<国际名人词典>> (第23版). 英国国际人物中心转记编辑出版,1994年. <<DICTIONARY OF INTERNATIONAL BIOGRAPHY>> (Twenty-third Edition).

    学会会员和社会兼职:
      1. 美国科学促进会(AAAS)(1998年)
      2. 美国基因治疗协会(ASGT)会员 (1999年)
      3. 美国 Sigma Xi 科学研究会会员(2000年)
      4. 美国癌症研究协会会员(AACR),(2004年)
      5. 美国临床癌症研究协会(ASCO)(2008年)
      6. 美国《Journal of Cancer》编委
      7. Board member,《Journal of Tumor》, Hong Kong
      8. 中华医学会肿瘤分会乳腺癌专业委员
      9. 国家自然科学基金委评审一审、二审专家
      10. 国家博士后基金评审专家
      11. 《Chinese Journal of Cancer》(癌症)责任编委
      12. 《中华乳腺病杂志》责任编委
      13. 广东省抗癌协会乳腺癌专业委员会常委
      14. 广东省医学会乳腺病分会常委
      15. 广东省医师协会乳腺专科医师工作委员会常委、
      16. 广东省自然科学基金委评审专家
      17. 广东省医学鉴定专家
      18. 广州市医疗事故技术鉴定专家

访客通道
员工通道
关注肿瘤医院